10-26-2015, 08:48 AM
(10-26-2015, 07:53 AM)rapidacid Wrote: I own GILD in my IRA and I'm "never" getting rid of it but here are a few points regarding the future of their revenue:
Quote:Growth is slowing due to price push back from insurance companies for the very flagship hepatitis C drugs Harvoni and Sovaldi we just discussed. Further, The Motley Fool reported that AbbVie's competing combination drug, Viekira Pak, is starting to capture larger market share. To quote the article, "Put simply, we may have already seen the high-water mark for Gilead's hep C franchise."
Worse yet, Gilead's HIV drugs have their critical patents expiring in the period 2018 to 2022. When patents expire, those same drugs become available under generic labels.
There was a news release last week about Viekira Pak causing deaths in certain patients with advanced liver disease. I don't see VP taking additional market share from Gilead any time soon.
Gilead also released news about Stage 3 trials for its next generation HIV drug Genvoya that is supposed to be less stressful to patients with similar positive effects. If this is approved it pushes the patent cliff back.